Şirket yükleniyor
Just reported
Q3 2026 results
From Amgen's results release of 3 Kasım 2026; its quarterly report has since been filed.
Revenue
Actual
$10,37B
+%8,5 y/y
+%3,1 q/qGuided
—
No guide given
EPS, GAAP
Actual
$7,08
+%19 y/y
+%62 q/qGuided
—
No guide given
Operating income, GAAP
Actual
$3,71B
+%47 y/y
+%5,6 q/qGuided
—
No guide given
Company outlook
Full year 2026
- Revenue$38,9B – $39,7B+%6,9 y/y Raised +%1,3
- EPS, adjusted$22,90 – $23,70Raised +%1,7
- EPS, GAAP$18,34 – $19,28+%32 y/y Raised +%14
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Amgen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company$1,35TA+
JNJJohnson & Johnson$682,6BA+
MRKMerck & Co., Inc.$362,2BA
NVSNovartis AG$305,8BA
GILDGilead Sciences, Inc.$208,3BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 Eki 2026CBGraded C, now B
MCKMckesson Corporation4 Kas 2026BAGraded B, now A
CVSCVS Health Corp4 Kas 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 Kas 2026BAGraded B, now A
BIIBBiogen Inc.28 Eki 2026BAGraded B, now A
Nasıl para kazanıyor
- Repatha prescription sales%9
- Otezla prescription sales%7
- Enbrel prescription sales%7
- EVENITY prescription sales%7
- XGEVA prescription sales%6
- TEPEZZA prescription sales%6
Gelir payları year ended 2025-12-31, high confidence dönemi için tahmindir; resmî bir bildirimden alınmış rakamlar değildir.
Rekabet ettiği şirketler
Ne satıyor6
Repatha
An injectable medicine that lowers LDL cholesterol and is used to reduce the chance of major heart and blood-vessel events in certain adults.
Prolia
A medicine for osteoporosis that helps reduce fracture risk in certain people, including postmenopausal women and men at high risk of fracture.
Otezla
An oral medicine used for plaque psoriasis, psoriatic arthritis and certain mouth ulcers.
3 tane daha göster
ENBREL
A medicine used for rheumatoid arthritis, plaque psoriasis and psoriatic arthritis.
TEZSPIRE
An antibody medicine used as an add-on treatment for severe uncontrolled asthma and, in approved markets, chronic sinus inflammation with nasal polyps.
IMDELLTRA
A cancer medicine for adults with extensive-stage small cell lung cancer that has progressed during or after platinum-based chemotherapy.
Kim alıyor3
- In the United States, Amgen sells substantially all its products to pharmaceutical wholesalers, which then distribute them to healthcare providers. McKesson, Cencora and Cardinal Health together accounted for 77% of worldwide gross revenue (year ended 2025-12-31, high confidence).
- Outside the United States, Amgen sells to healthcare providers and pharmaceutical wholesalers, depending on local distribution practices.
- Healthcare providers, including physicians and their clinics, hospitals, dialysis centers and pharmacies, use or dispense Amgen medicines; some products are also marketed through direct-to-patient channels.
Neye dayanıyor ve onu ne yıkabilir
Faaliyetin dayandığı şeyler
- 1Amgen relies on large wholesalers for distribution: McKesson, Cencora and Cardinal Health together accounted for 77% of worldwide gross revenue (year ended 2025-12-31, high confidence).
- 2The United States is its largest market, accounting for 71.9% of revenue by geography (year ended 2025-12-31, high confidence).
- 3Its sales depend on government and commercial insurers covering its medicines and deciding how much they will reimburse; coverage rules and required discounts can affect use and net prices.
- 4The 10-K says a substantial majority of commercial manufacturing takes place in Puerto Rico and a substantial majority of clinical manufacturing takes place in Thousand Oaks, California.
- 5Amgen relies on third-party suppliers for some raw materials, devices and components, including items for which a supplier may be its only source.
Ters gidebilecekler
- 1Government and private payer policies can limit access or reduce the prices Amgen receives. The filings describe Medicare price setting for ENBREL and Otezla, expanded discounts through the 340B program, and other pricing policies as pressures on sales and profitability.
- 2Biosimilar and generic competition can reduce sales and prices. The patents for Prolia and XGEVA have expired in key markets, and the 10-Q reports lower sales as biosimilar competitors entered those markets.
- 3Manufacturing disruption could limit medicine supply and sales. The 10-K identifies concentration of commercial manufacturing in Puerto Rico and clinical manufacturing in Thousand Oaks, California, as potential sources of disruption.
Amgen Inc. hakkında
Amgen researches, develops and manufactures medicines, including biologic medicines made using living cells and small-molecule drugs. It sells treatments for conditions including heart disease, cancer, osteoporosis, asthma and autoimmune diseases. It also sells biosimilar medicines, which are highly similar versions of existing biologic medicines.
- Merkez
- Thousand Oaks, California
- Kuruluş
- 1980 (incorporated in California; high confidence)
- İşlem gördüğü borsa
- NASDAQ
- Mali yıl sonu
- December 31
Amgen Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
